Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + EV vs Pembrolizumab + EV in Untreated Advanced Urothelial Carcinoma
NCT07815665Phase 3Recruiting
- Sponsor
- Summit Therapeutics
- Start
- Sep 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in urothelial carcinoma (UC), sponsored by Summit Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07815665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815665.